Warning Letter Roundup & Recap – December 8, 2015
This article was originally published in The Gray Sheet
No device warning letters were released by FDA this week.
You may also be interested in...
Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing ‘behind us’ with a legislative compromise.
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.
No device-related warning letters were released by the US FDA the week of 19 January.